Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Trial Participants in the U.S.
- Statement
- COVID-19
Sep 17, 2021
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
- COVID-19
Sep 16, 2021
Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan
- Statement
- COVID-19
Sep 10, 2021
Novavax to Participate in Upcoming September Conferences
- Corporate and Finance
Sep 9, 2021
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
- COVID-19
Sep 8, 2021
Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
- Corporate and Finance
Sep 7, 2021
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
- COVID-19
Aug 30, 2021
Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
- COVID-19
Aug 25, 2021
Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
- Corporate and Finance
Aug 16, 2021
Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights

Aug 5, 2021

Show per page